Ratio of Mediastinal Lymph Node SUV to Primary Tumor SUV in F-FDG PET/CT for Nodal Staging in Non-Small-Cell Lung Cancer

Overview

Journal Nucl Med Mol Imaging

Publisher Springer

Date 2017 Jun 1

PMID 28559938

Citations 9

Authors

Jaehyuk Cho

Jae Gol Choe

Kisoo Pahk

Sunju Choi

Hye Ryeong Kwon

Jae Seon Eo

Hyo Jung Seo

Chulhan Kim

Sungeun Kim

Affiliations

Soon will be listed here.

Abstract

Purpose: Following determination of the maximum standardized uptake values (SUVmax) of the mediastinal lymph nodes (SUV-LN) and of the primary tumor (SUV-T) on F-FDG PET/CT in patients with non-small-cell lung cancer (NSCLC), the aim of the study was to determine the value of the SUV-LN/SUV-T ratio in lymph node staging in comparison with that of SUV-LN.

Methods: We retrospectively reviewed a total of 289 mediastinal lymph node stations from 98 patients with NSCLC who were examined preoperatively for staging and subsequently underwent pathologic studies of the mediastinal lymph nodes. We determined SUV-LN and SUV-R for each lymph node station on F-FDG PET/CT and then classified each station into one of three groups based on SUV-T (low, medium and high SUV-T groups). Diagnostic performance was assessed based on receiver operating characteristic (ROC) curve analysis, and the optimal cut-off values that would best discriminate metastatic from benign lymph nodes were determined for each method.

Results: The average of SUV-R of malignant lymph nodes was significantly higher than that of benign lymph nodes (0.79 ± 0.45 vs. 0.36 ± 0.23, < 0.0001). In the ROC curve analysis, the area under the curve (AUC) of SUV-R was significantly higher than that of SUV-LN in the low SUV-T group (0.885 vs. 0.810, = 0.019). There were no significant differences between the AUCs of SUV-LN and of SUV-R in the medium and high SUV-T groups. The optimal cut-off value for SUV-R in the low SUV-T group was 0.71 (sensitivity 87.5 %, specificity 85.9 %).

Conclusions: The SUV-R performed well in distinguishing between metastatic and benign lymph nodes. In particular, SUV-R was found to have a better diagnostic performance than SUV-LN in the low SUV-T group.

Citing Articles

Is CT Radiomics Superior to Morphological Evaluation for pN0 Characterization? A Pilot Study in Colon Cancer.

Zerunian M, Nacci I, Caruso D, Polici M, Masci B, De Santis D Cancers (Basel). 2024; 16(3).

PMID: 38339411 PMC: 10854865. DOI: 10.3390/cancers16030660.

Comparison of the diagnostic value of [ Ga]Ga-FAPI-04 PET/MR and [F]FDG PET/CT in patients with T stage ≤ 2a2 uterine cervical cancer: a prospective study.

Lyu Y, Chen X, Liu H, Xi Y, Feng W, Li B Eur J Nucl Med Mol Imaging. 2023; 51(4):1163-1172.

PMID: 38032383 DOI: 10.1007/s00259-023-06539-z.

Additional Value of PET and CT Image-Based Features in the Detection of Occult Lymph Node Metastases in Lung Cancer: A Systematic Review of the Literature.

Guglielmo P, Marturano F, Bettinelli A, Sepulcri M, Pasello G, Gregianin M Diagnostics (Basel). 2023; 13(13).

PMID: 37443547 PMC: 10340586. DOI: 10.3390/diagnostics13132153.

Prospective Evaluation of Quantitative F-18-FDG-PET/CT for Pre-Operative Thoracic Lymph Node Staging in Patients with Lung Cancer as a Target for Computer-Aided Diagnosis.

Genseke P, Wielenberg C, Schreiber J, Luecke E, Frese S, Walles T Diagnostics (Basel). 2023; 13(7).

PMID: 37046481 PMC: 10093566. DOI: 10.3390/diagnostics13071263.

A Comparative Evaluation of Mediastinal Nodal SUVmax and Derived Ratios from F-FDG PET/CT Imaging to Predict Nodal Metastases in Non-Small Cell Lung Cancer.

AlRasheedi M, Han S, Thygesen H, Neilson M, Hendry F, Alkarn A Diagnostics (Basel). 2023; 13(7).

PMID: 37046427 PMC: 10093125. DOI: 10.3390/diagnostics13071209.

References

Shim S, Lee K, Kim B, Chung M, Lee E, Han J . Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging. Radiology. 2005; 236(3):1011-9. DOI: 10.1148/radiol.2363041310. View

Turkmen C, Sonmezoglu K, Toker A, Yilmazbayhan D, Dilege S, Halac M . The additional value of FDG PET imaging for distinguishing N0 or N1 from N2 stage in preoperative staging of non-small cell lung cancer in region where the prevalence of inflammatory lung disease is high. Clin Nucl Med. 2007; 32(8):607-12. DOI: 10.1097/RLU.0b013e3180a1ac87. View

Chin B, Green E, Turkington T, Hawk T, Coleman R . Increasing uptake time in FDG-PET: standardized uptake values in normal tissues at 1 versus 3 h. Mol Imaging Biol. 2008; 11(2):118-22. DOI: 10.1007/s11307-008-0177-9. View

Budiawan H, Cheon G, Im H, Lee S, Paeng J, Kang K . Heterogeneity Analysis of (18)F-FDG Uptake in Differentiating Between Metastatic and Inflammatory Lymph Nodes in Adenocarcinoma of the Lung: Comparison with Other Parameters and its Application in a Clinical Setting. Nucl Med Mol Imaging. 2014; 47(4):232-41. PMC: 4035177. DOI: 10.1007/s13139-013-0216-6. View

Kumar A, Dutta R, Kannan U, Kumar R, Khilnani G, Gupta S . Evaluation of mediastinal lymph nodes using F-FDG PET-CT scan and its histopathologic correlation. Ann Thorac Med. 2011; 6(1):11-6. PMC: 3023864. DOI: 10.4103/1817-1737.74270. View

Ernst A, Anantham D, Eberhardt R, Krasnik M, Herth F . Diagnosis of mediastinal adenopathy-real-time endobronchial ultrasound guided needle aspiration versus mediastinoscopy. J Thorac Oncol. 2008; 3(6):577-82. DOI: 10.1097/JTO.0b013e3181753b5e. View

Clementsen P, Skov B, Vilmann P, Krasnik M . Endobronchial ultrasound-guided biopsy performed under optimal conditions in patients with known or suspected lung cancer may render mediastinoscopy unnecessary. J Bronchology Interv Pulmonol. 2014; 21(1):21-5. DOI: 10.1097/LBR.0000000000000028. View

Ost D, Yeung S, Tanoue L, Gould M . Clinical and organizational factors in the initial evaluation of patients with lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143(5 Suppl):e121S-e141S. PMC: 4694609. DOI: 10.1378/chest.12-2352. View

Iskender I, Kadioglu S, Kosar A, Atasalihi A, Kir A . Is there any maximum standardized uptake value variation among positron emission tomography scanners for mediastinal staging in non-small cell lung cancer?. Interact Cardiovasc Thorac Surg. 2011; 12(6):965-9. DOI: 10.1510/icvts.2010.258103. View

10.

Park J, Byun B, Noh W, Lee S, Kim H, Kim E . Lymph node to primary tumor SUV ratio by 18F-FDG PET/CT and the prediction of axillary lymph node metastases in breast cancer. Clin Nucl Med. 2013; 39(4):e249-53. DOI: 10.1097/RLU.0b013e3182a75477. View

11.

Ettinger D, Wood D, Akerley W, Bazhenova L, Borghaei H, Camidge D . Non-Small Cell Lung Cancer, Version 6.2015. J Natl Compr Canc Netw. 2015; 13(5):515-24. DOI: 10.6004/jnccn.2015.0071. View

12.

Steinert H, Hauser M, Allemann F, Engel H, Berthold T, von Schulthess G . Non-small cell lung cancer: nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling. Radiology. 1997; 202(2):441-6. DOI: 10.1148/radiology.202.2.9015071. View

13.

Cerfolio R, Bryant A . Ratio of the maximum standardized uptake value on FDG-PET of the mediastinal (N2) lymph nodes to the primary tumor may be a universal predictor of nodal malignancy in patients with nonsmall-cell lung cancer. Ann Thorac Surg. 2007; 83(5):1826-9. DOI: 10.1016/j.athoracsur.2006.12.034. View

14.

Wahl R, Quint L, Greenough R, Meyer C, White R, Orringer M . Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation. Radiology. 1994; 191(2):371-7. DOI: 10.1148/radiology.191.2.8153308. View

15.

Lee A, Choi S, Jung K, Park J, Lee S, Bae S . Characteristics of Metastatic Mediastinal Lymph Nodes of Non-Small Cell Lung Cancer on Preoperative F-18 FDG PET/CT. Nucl Med Mol Imaging. 2014; 48(1):41-6. PMC: 4035153. DOI: 10.1007/s13139-013-0244-2. View

16.

Adams M, Turkington T, Wilson J, Wong T . A systematic review of the factors affecting accuracy of SUV measurements. AJR Am J Roentgenol. 2010; 195(2):310-20. DOI: 10.2214/AJR.10.4923. View

17.

Medford A, Bennett J, Free C, Agrawal S . Mediastinal staging procedures in lung cancer: EBUS, TBNA and mediastinoscopy. Curr Opin Pulm Med. 2009; 15(4):334-42. DOI: 10.1097/MCP.0b013e32832b8a45. View

18.

Navani N, Lawrence D, Kolvekar S, Hayward M, McAsey D, Kocjan G . Endobronchial ultrasound-guided transbronchial needle aspiration prevents mediastinoscopies in the diagnosis of isolated mediastinal lymphadenopathy: a prospective trial. Am J Respir Crit Care Med. 2012; 186(3):255-60. PMC: 3423452. DOI: 10.1164/rccm.201203-0393OC. View

19.

Yasufuku K, Pierre A, Darling G, de Perrot M, Waddell T, Johnston M . A prospective controlled trial of endobronchial ultrasound-guided transbronchial needle aspiration compared with mediastinoscopy for mediastinal lymph node staging of lung cancer. J Thorac Cardiovasc Surg. 2011; 142(6):1393-400.e1. DOI: 10.1016/j.jtcvs.2011.08.037. View

20.

Silvestri G, Gould M, Margolis M, Tanoue L, McCrory D, Toloza E . Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest. 2007; 132(3 Suppl):178S-201S. DOI: 10.1378/chest.07-1360. View